Shionogi Company Limited

Hiroyuki Tobinaga

Koji Masuda

Manami Masuda

Masanao Inagaki

Hiroyuki Kai

Yoshiyuki Taoda

Motohiro Fujiu

Takeshi Endoh

Kayoko Hata

Daisuke Taniyama

Yoshio Hato

Kentaro Asahi

Mitsuhiro Yonehara

Satoshi Kasuya

Hiromi Nakai

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein

Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect

Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)': wherein A is S or O; Ris substituted or unsubstituted alkyloxy or the like, Rto Rare each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, Ris each independently halogen or the like, r is an integer of 0 to 4, Ris substituted or unsubstituted aromatic heterocyclyl or the like,or a pharmaceutically acceptable salt thereof.

Condensed ring compounds having dopamine D3 receptor antagonistic effect

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): whereinring A is a heterocycle, Xis each independently CRR, Xis each independently CRR, Yand Yare each independently a carbon atom or a nitrogen atom,L is &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014; or the like, W is cyclyl or the like, Rand Rare each independently substituted or unsubstituted alkyl or the like, R, R, Rto R, and Rare each independently hydrogen atoms or the like,p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): 

The present invention is related to a compound represented by formula (I), 

Heterocyclic derivative having PGD2 receptor antagonist activity

The present invention provides a novel P2Xand/or P2X/receptor antagonist. A compound represented by the formula (I): wherein Zis optionally protected hydroxy, etc.; Zis &#x2014;C(&#x2550;O)&#x2014;, etc.; Zand Zare taken together &#x2550;O or &#x2550;S; t is an integer of 0 to 4; Rand Rare each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; Rand Rare each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; Ris substituted or unsubstituted alkyl, etc.; Ris substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.

Growing community of inventors

Osaka, Japan

Hiroyuki Tobinaga